Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

SUMMARY: Odanacatib is a cathepsin K inhibitor investigated for the treatment of postmenopausal osteoporosis. Phase 2 data indicate that 50 mg once weekly inhibits bone resorption and increases bone mineral density, with only a transient decrease in bone formation. We describe the background, design...

Descripción completa

Detalles Bibliográficos
Autores principales: Bone, H. G., Dempster, D. W., Eisman, J. A., Greenspan, S. L., McClung, M. R., Nakamura, T., Papapoulos, S., Shih, W. J., Rybak-Feiglin, A., Santora, A. C., Verbruggen, N., Leung, A. T., Lombardi, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312384/
https://www.ncbi.nlm.nih.gov/pubmed/25432773
http://dx.doi.org/10.1007/s00198-014-2944-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312384/
https://www.ncbi.nlm.nih.gov/pubmed/25432773
http://dx.doi.org/10.1007/s00198-014-2944-6

Ejemplares similares